Table I.
Association between CDCA5 expression and the clinical characteristics of 137 patients with ccRCC.
| Characteristic | No. of patients (%) | CDCA5 expression
|
χ2 value | P-value | |
|---|---|---|---|---|---|
| Low (%) | High (%) | ||||
| Number of patients | 137 | 85 | 52 | ||
| Age (years) | |||||
| ≤60 | 104 (75.9) | 66 (77.6) | 38 (73.1) | 0.369 | 0.544 |
| >60 | 33 (24.1) | 19 (22.4) | 14 (26.9) | ||
| Sex | |||||
| Male | 103 (75.2) | 66 (77.6) | 37 (71.2) | 0.729 | 0.393 |
| Female | 34 (24.8) | 19 (22.4) | 15 (28.8) | ||
| BMI | |||||
| <28 | 101 (73.7) | 62 (72.9) | 39 (75.0) | 0.071 | 0.79 |
| ≥28 | 36 (26.3) | 23 (27.1) | 13 (25.0) | ||
| T stage | |||||
| T1 | 111 (81.0) | 75 (88.2) | 36 (69.2) | 7.578 | 0.006 |
| T2-T4 | 26 (19.0) | 10 (12.8) | 16 (30.8) | ||
| N stage | |||||
| N1 | 6 (4.4) | 1 (1.2) | 5 (9.6) | 3.656 | 0.056 |
| N0 | 131 (95.6) | 84 (98.8) | 47 (90.4) | ||
| M stage | |||||
| M1 | 13 (9.5) | 2 (2.4) | 11 (21.2) | 13.278 | <0.001 |
| M0 | 124 (90.5) | 83 (97.6) | 41 (78.8) | ||
| AJCC stage | |||||
| I-II | 113 (82.5) | 82 (96.5) | 31 (59.6) | 30.328 | <0.001 |
| III-IV | 24 (17.5) | 3 (3.5) | 21 (40.4) | ||
| WHO/ISUP Grade | |||||
| I-II/Low | 113 (82.5) | 80 (94.1) | 26 (50.0) | 35.867 | <0.001 |
| III-IV/High | 24 (17.5) | 5 (5.9) | 26 (50.0) | ||
Values in bold font indicate statistical significance (P<0.05). BMI, body mass index; T, primary tumor size; N, lymph node metastasis; M, distant metastasis; CDCA5, cell division cycle-associated 5; ccRCC, clear cell renal cell carcinoma.